All In Biotech

Drug Trial Radar · NCT06436534

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 24, 2024

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the clinical efficacy and safety of ganciclovir (GCV) capsules in the treatment of refractory moderate-to-severe allergic rhinitis. The main questions it aims to answer are: 1. Whether ganciclovir improve nasal symptoms and life quality in patients with refractory moderate-to-severe allergic rhinitis. 2. Whether ganciclovir is safe for the treatment of allergic rhinitis. Participants with refractory moderate-to-severe allergic rhinitis will be included in the trial based on the inclusion and exclusion criteria, and randomized into experimental and control groups. The two groups will be treated with blinded ganciclovir capsules or placebo for two weeks, with the background therapy of mometasone furoate aqueous nasal spray. A placebo is a look-alike capsule that contains no active drug. Nasal symptom scores, nasal secretions, blood samples and adverse events will be collected during the visits. Researchers will compare the experimental and control groups to see whether ganciclovir improve symptoms and is safe for the treatment of refractory moderate-to-severe allergic rhinitis.

Conditions

  • Rhinitis, Allergic

Interventions

  • Ganciclovir Oral CapsuleDrug

    2-week treatment phase:Ganciclovir capsules(250mg), take 2 capsules twice a day

  • Ganciclovir Simulant Oral CapsuleDrug

    2-week treatment phase:Ganciclovir simulant capsules(0mg), take 2 capsules twice a day

  • Mometasone NasalDrug

    From screening phase to follow-up phase:Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of improvement in TNSS scoresTime frame: From baseline to the end of treatment phase(2 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wuhan Union Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.